LQDA
Price
$16.53
Change
-$0.34 (-2.02%)
Updated
Jun 3 closing price
Capitalization
1.41B
64 days until earnings call
XERS
Price
$4.65
Change
-$0.40 (-7.92%)
Updated
Jun 3 closing price
Capitalization
744.72M
63 days until earnings call
Interact to see
Advertisement

LQDA vs XERS

Header iconLQDA vs XERS Comparison
Open Charts LQDA vs XERSBanner chart's image
Liquidia
Price$16.53
Change-$0.34 (-2.02%)
Volume$2.39M
Capitalization1.41B
Xeris Biopharma Holdings
Price$4.65
Change-$0.40 (-7.92%)
Volume$5.1M
Capitalization744.72M
LQDA vs XERS Comparison Chart
Loading...
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LQDA vs. XERS commentary
Jun 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LQDA is a StrongBuy and XERS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2025
Stock price -- (LQDA: $16.53 vs. XERS: $4.65)
Brand notoriety: LQDA and XERS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LQDA: 140% vs. XERS: 196%
Market capitalization -- LQDA: $1.41B vs. XERS: $744.72M
LQDA [@Biotechnology] is valued at $1.41B. XERS’s [@Biotechnology] market capitalization is $744.72M. The market cap for tickers in the [@Biotechnology] industry ranges from $321.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LQDA’s FA Score shows that 0 FA rating(s) are green whileXERS’s FA Score has 0 green FA rating(s).

  • LQDA’s FA Score: 0 green, 5 red.
  • XERS’s FA Score: 0 green, 5 red.
According to our system of comparison, LQDA is a better buy in the long-term than XERS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LQDA’s TA Score shows that 5 TA indicator(s) are bullish while XERS’s TA Score has 6 bullish TA indicator(s).

  • LQDA’s TA Score: 5 bullish, 5 bearish.
  • XERS’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, XERS is a better buy in the short-term than LQDA.

Price Growth

LQDA (@Biotechnology) experienced а +5.96% price change this week, while XERS (@Biotechnology) price change was -3.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.76%. For the same industry, the average monthly price growth was +2.77%, and the average quarterly price growth was +0.74%.

Reported Earning Dates

LQDA is expected to report earnings on Aug 07, 2025.

XERS is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+5.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LQDA($1.41B) has a higher market cap than XERS($745M). LQDA YTD gains are higher at: 40.561 vs. XERS (37.168). XERS has higher annual earnings (EBITDA): -13.99M vs. LQDA (-122.53M). LQDA has more cash in the bank: 170M vs. XERS (71.6M). LQDA has less debt than XERS: LQDA (148M) vs XERS (271M). XERS has higher revenues than LQDA: XERS (203M) vs LQDA (14.1M).
LQDAXERSLQDA / XERS
Capitalization1.41B745M190%
EBITDA-122.53M-13.99M876%
Gain YTD40.56137.168109%
P/E RatioN/AN/A-
Revenue14.1M203M7%
Total Cash170M71.6M237%
Total Debt148M271M55%
FUNDAMENTALS RATINGS
LQDA vs XERS: Fundamental Ratings
LQDA
XERS
OUTLOOK RATING
1..100
6965
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
3466
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4537
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LQDA's Valuation (82) in the Pharmaceuticals Major industry is in the same range as XERS (91). This means that LQDA’s stock grew similarly to XERS’s over the last 12 months.

LQDA's Profit vs Risk Rating (34) in the Pharmaceuticals Major industry is in the same range as XERS (66). This means that LQDA’s stock grew similarly to XERS’s over the last 12 months.

LQDA's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as XERS (100). This means that LQDA’s stock grew similarly to XERS’s over the last 12 months.

XERS's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as LQDA (45). This means that XERS’s stock grew similarly to LQDA’s over the last 12 months.

XERS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as LQDA (100). This means that XERS’s stock grew similarly to LQDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LQDAXERS
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
68%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 20 days ago
85%
Bullish Trend 19 days ago
85%
Declines
ODDS (%)
Bearish Trend 12 days ago
84%
Bearish Trend 13 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
72%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GHTMX15.07N/A
N/A
Goldman Sachs International T/M Eq Instl
AHSCX11.33N/A
N/A
Alger Health Sciences C
AUUIX22.19N/A
N/A
AB Select US Equity I
YAFIX19.42N/A
N/A
AMG Yacktman Focused I
WCMIX26.30N/A
N/A
WCM Focused International Growth Instl

LQDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LQDA has been loosely correlated with ALNY. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if LQDA jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LQDA
1D Price
Change %
LQDA100%
-2.02%
ALNY - LQDA
37%
Loosely correlated
-0.76%
AXON - LQDA
32%
Poorly correlated
+0.07%
AVXL - LQDA
30%
Poorly correlated
+3.70%
XERS - LQDA
29%
Poorly correlated
-7.92%
KURA - LQDA
29%
Poorly correlated
+1.90%
More

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with TRDA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
-7.92%
TRDA - XERS
51%
Loosely correlated
+1.23%
XNCR - XERS
48%
Loosely correlated
+6.53%
KRYS - XERS
47%
Loosely correlated
+4.43%
CGON - XERS
47%
Loosely correlated
+0.75%
YMAB - XERS
45%
Loosely correlated
+2.74%
More